Search
Outlook Therapeutics Inc
OTLKAdd to Watchlist
0.513USD
-0.006-1.16%
Close 10-26 16:00（ET）
124.89MMarket Cap
LossP/E TTM
Today
-1.16%
5 Days
+4.06%
1 Month
-19.84%
6 Months
+62.86%
Year to Date
-67.53%
1 Year
-63.09%
Key Figures
0.512Open
0.529High
284.37KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.12%Turnover Ratio
0.519Prev. Close
0.487Low
142.31KTurnover
LossP/E Static
-11.83P/B
0.00%Div Yield TTM
-297.58%ROA
2.53852wk High
0.09Volume Ratio
-75.37MNet Profit
243.45MShares
-1.1289EPS TTM
0.86Beta
-827.71%ROE
0.16152wk Low
14.07%Amplitude
-95.00%Gross Margin
124.89MMarket Cap
-5.41Reward/Risk
9.61%Risk Rate
Outlook Therapeutics Inc's Score
-0.02vs previous score
Forecast7.00
Financial Health5.70
Technical5.13
Valuation Dimensions9.45
Institutional Confidence3.00
Risk Assessment2.72
Media Coverage
Coverage Level
Very Low
Very High
Neutral
Analyst Rating
Outlook Therapeutics Inc Technical Analysis
Technical Indicators
Sell
Summary
Sell
Moving Average
Strong sell
Outlook Therapeutics Inc Latest Earnings Call Transcripts
Outlook Therapeutics (OTLK) Fiscal Q3 2026 Earnings Call: LYTENAVA Launch and Revenue Guidance
Outlook Therapeutics’ fiscal Q3 2026 earnings call covered LYTENAVA’s FDA approval, U.S. launch plans, $50M-$75M first-year revenue guidance and financing.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-0.15/-0.09
Revenue / Forecast
8.70K/5.30M
Outlook Therapeutics Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolOTLK
Number of employees23
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| GMS Ventures and Investments | 11.22% |
| Intracoastal Capital, L.L.C. | 4.25% |
| Schonfeld Strategic Advisors LLC | 2.02% |
| Vanguard Capital Management, LLC | 1.63% |
| Shareholder Types | Proportion |
|---|---|
| Corporation | 15.48% |
| Investment Advisor | 3.65% |
| Hedge Fund | 2.41% |
| Investment Advisor/Hedge Fund | 0.73% |
Related Instruments
+0.45%
+0.94%
+0.39%
-3.21%
+1.78%
+0.33%
+1.22%
+1.70%
+0.20%
-0.80%
-1.23%
+0.21%
-0.79%
+0.69%
+0.46%
+0.33%
-0.62%
+0.94%
+0.79%
-0.50%
FAQs
What is the current price of Outlook Therapeutics Inc (OTLK)?
The current price of Outlook Therapeutics Inc (OTLK) is 0.51.
What is the symbol of Outlook Therapeutics Inc?
The ticker symbol of Outlook Therapeutics Inc is OTLK.
What is the 52-week high of Outlook Therapeutics Inc?
The 52-week high of Outlook Therapeutics Inc is 2.54.
What is the 52-week low of Outlook Therapeutics Inc?
The 52-week low of Outlook Therapeutics Inc is 0.16.
What is the market capitalization of Outlook Therapeutics Inc?
The market capitalization of Outlook Therapeutics Inc is 124.89M.
Is Outlook Therapeutics Inc (OTLK) currently rated as Buy, Hold, or Sell?
According to analysts, Outlook Therapeutics Inc (OTLK) has an overall rating of Buy, with a price target of 5.03.
What is the Earnings Per Share (EPS TTM) of Outlook Therapeutics Inc (OTLK)?
The Earnings Per Share (EPS TTM) of Outlook Therapeutics Inc (OTLK) is -1.13.